7BZ5

Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody

7BZ5 の概要

• エントリーDOI: 10.2210/pdb7bz5/pdb
• 分子名称: Spike protein S1, Heavy chain of B38, Light chain of B38, ... (5 entities in total)
• 機能のキーワード: covid-19 antibody, viral protein, viral protein-immune system complex, viral protein/immune system
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV); 詳細
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 73360.00

構造登録者

Wu, Y.,Qi, J.,Gao, F. (登録日: 2020-04-26, 公開日: 2020-05-13, 最終更新日: 2024-10-30)

主引用文献

Wu, Y.,Wang, F.,Shen, C.,Peng, W.,Li, D.,Zhao, C.,Li, Z.,Li, S.,Bi, Y.,Yang, Y.,Gong, Y.,Xiao, H.,Fan, Z.,Tan, S.,Wu, G.,Tan, W.,Lu, X.,Fan, C.,Wang, Q.,Liu, Y.,Zhang, C.,Qi, J.,Gao, G.F.,Gao, F.,Liu, L.
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.
Science, 368:1274-1278, 2020

PubMed Abstract: Neutralizing antibodies could potentially be used as antivirals against the coronavirus disease 2019 (COVID-19) pandemic. Here, we report isolation of four human-origin monoclonal antibodies from a convalescent patient, all of which display neutralization abilities. The antibodies B38 and H4 block binding between the spike glycoprotein receptor binding domain (RBD) of the virus and the cellular receptor angiotensin-converting enzyme 2 (ACE2). A competition assay indicated different epitopes on the RBD for these two antibodies, making them a potentially promising virus-targeting monoclonal antibody pair for avoiding immune escape in future clinical applications. Moreover, a therapeutic study in a mouse model validated that these antibodies can reduce virus titers in infected lungs. The RBD-B38 complex structure revealed that most residues on the epitope overlap with the RBD-ACE2 binding interface, explaining the blocking effect and neutralizing capacity. Our results highlight the promise of antibody-based therapeutics and provide a structural basis for rational vaccine design.

PubMed: 32404477
DOI: 10.1126/science.abc2241

実験手法

X-RAY DIFFRACTION (1.84 Å)